OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC By Ogkologos - April 14, 2026 237 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR News digest – dinosaur bone cancer, YouTube junk food ad ban... August 8, 2020 FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma November 4, 2022 Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy... June 17, 2025 Efficacy Outcomes of Olaparib in Patients with mCRPC with BRCA Alterations... November 21, 2023 Load more HOT NEWS Ενθαρρυντικά δεδομένα για ασθενείς με προχωρημένο μελάνωμα που έλαβαν θεραπεία με... Girl Scout’s Pink Chair Project Loans Recliners to Women Recovering from... Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI
